bioLytical INSTI HIV-1/HIV-2 Antibody Test

The Florida Department of Health (FDOH), Bureau of Communicable Disease (BCD), HIV/AIDS Section, is seeking to procure FDA-approved, 3rd generation rapid HIV testing devices from bioLytical that provide results in 60 seconds. The devices are intended for use in at-risk communities and for testing kit training. The contract term is for 3 years, and the estimated dollar amount for this single-source purchase is $3,000,000. The FDOH has determined that these 60-second, 3rd generation rapid HIV testing devices are only available from bioLytical and are necessary for the HIV/AIDS Section's testing program. The FDOH is also seeking to purchase a preventative maintenance and service agreement for this equipment from Agilent Technologies as a single source. The procurement process includes a due date of March 12, 2023, for responses.

This procurement is designated as a single-source purchase, as the FDOH has determined that the 60-second, 3rd generation rapid HIV testing devices are only available from bioLytical. There are no set-aside designations or restrictions on the types of organizations that can respond. The current incumbent vendor is bioLytical, and the FDOH is also seeking to purchase a preventative maintenance and service agreement from Agilent Technologies. The total estimated value of the contract is $3,000,000.